Decitabine Treatment for XMEN Disease in Children
Treatments studied
Part of Genetic & congenital, Immune system & allergy clinical trials.
This trial tests whether a drug called decitabine can safely treat XMEN disease, a rare genetic immune condition that affects boys. The study looks at whether decitabine helps with liver problems and infections caused by the Epstein-Barr virus (EBV).
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a boy between 1 month and 18 years old
- Have a confirmed MAGT1 gene mutation (diagnosed by genetic testing)
- Have symptoms of XMEN disease, such as liver problems and/or EBV infection
- Have low levels of a specific immune marker called NKG2D on white blood cells
- Be in generally stable health with normal vital signs
- Be able to live at least 6 more months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (decitabine and venetoclax) at a very low, extended dose for people aged 60 or older who have been newly diagnosed with acute myeloid leukemia or high-risk myelodysplastic syndrome. The goal is to see if this gentler approach is effective and well-tolerated.
This Phase 1 trial studies how a pill form of decitabine/cedazuridine behaves in the body and how safe it is for people whose livers don’t work normally. It may help doctors better understand dosing and safety in patients with hepatic impairment.
This Phase 2 trial tests whether adding decitabine to one of three targeted medicines (ruxolitinib, fedratinib, or pacritinib) can improve outcomes in people with advanced myeloproliferative neoplasms that are progressing to a blast phase. It may help control the disease by combining blood-cancer chemotherapy with drugs that block disease-driving signaling.
This Phase 1 trial studies how an oral combination cancer medicine behaves in the body (dose handling and safety) in people with kidney impairment. It may help doctors learn the safest way to use this treatment when kidney function is reduced.
This early-phase trial tests whether a combination of targeted medicines can improve outcomes in people with higher-risk MDS or certain types of AML or CMML. It’s designed to find the safest dose and learn if the treatment can help the cancer respond.
This study tests whether adding a new drug called iadademstat to the standard treatment ASTX727 helps people with advanced myeloproliferative neoplasms (blood cancers that cause the bone marrow to make too many cells). The goal is to see if the combination is safe and works better than the standard treatment alone.
Hear when a new MAGT1 Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.